Similar articles

• Icodextrin - still a cause for concern with blood glucose monitoring in continuous ambulatory peritoneal dialysis patients with diabetes.

  Slim S, Griffiths MJ, Gama R. Slim S, et al. Ann Clin Biochem. 2007 Mar;44(Pt 2):196-7. doi: 10.1258/000456307780117957. Ann Clin Biochem. 2007. PMID: 17362588 No abstract available.
• Comparison of peritoneal dialysis solutions.

  Crawford-Bonadio TL, Diaz-Buxo JA. Crawford-Bonadio TL, et al. Nephrol Nurs J. 2004 Sep-Oct;31(5):499-507, 520; quiz 508-9. Nephrol Nurs J. 2004. PMID: 15518252 Review.
• Novel peritoneal dialysis solutions--what are the clinical implications?

  Jörres A. Jörres A. Blood Purif. 2012;33(1-3):153-9. doi: 10.1159/000334151. Epub 2012 Jan 20. Blood Purif. 2012. PMID: 22269466
• [Icodextrin as first treatment: reasons to be optimistic].

  Rivera M. Rivera M. Nefrologia. 2009;29(2):99-102. doi: 10.3265/Nefrologia.2009.29.2.5243.en.full. Nefrologia. 2009. PMID: 19396313 Spanish. No abstract available.
• [Glucose polymer (icodextrin) as a component of fluid for peritoneal dialysis].

  Czyzewska K, Szary B, Grzegorzewska A. Czyzewska K, et al. Pol Arch Med Wewn. 1998 May;99(5):417-22. Pol Arch Med Wewn. 1998. PMID: 9816893 Review. Polish. No abstract available.